Search results
Results from the WOW.Com Content Network
Trials in emergency department settings support the use of ondansetron to abort vomiting episodes associated with gastroenteritis and dehydration. [20] A randomized controlled trial using a single dose of oral ondansetron in children with presumably viral gastroenteritis found it to be highly effective in stopping vomiting and increasing the effectiveness of oral rehydration therapy, thereby ...
The Child and Adolescent Symptom Inventory (CASI) is a behavioral rating checklist created by Kenneth Gadow and Joyce Sprafkin that evaluates a range of behaviors related to common emotional and behavioral disorders identified in the Diagnostic and Statistical Manual of Mental Disorders (DSM), including attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder ...
If the template has a separate documentation page (usually called "Template:template name/doc"), add [[Category:Medical symptoms and signs templates]] to the <includeonly> section at the bottom of that page. Otherwise, add <noinclude>[[Category:Medical symptoms and signs templates]]</noinclude>
The Pediatric Symptom Checklist (PSC) is a 35-item parent-report questionnaire designed to identify children with difficulties in psychosocial functioning. Its primary purpose is to alert pediatricians at an early point about which children would benefit from further assessment. [ 1 ]
During an acute FPIES episode, if symptoms are mild (1-2 vomiting episodes), ondansetron or infacol may be given to control vomiting in children over 6 months of age, along with oral rehydration. If vomiting persists or if a child has more severe symptoms (i.e., lethargy, pallor, hypotonia), then the child should be taken to an emergency room ...
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
Ondansetron was approved by the U.S. Food and Drug Administration in 1991, and has since become available in several other countries, including the UK, Ireland, Australia, Canada, France and Brazil. As of 2008, ondansetron and granisetron are the only 5-HT 3 antagonists available as a generic drug in the United States. Ondansetron may be given ...
To change this template's initial visibility, the |state= parameter may be used: {{Infectious disease symptoms and signs | state = collapsed}} will show the template collapsed, i.e. hidden apart from its title bar. {{Infectious disease symptoms and signs | state = expanded}} will show the template expanded, i.e. fully visible.